Showing 1751-1760 of 3305 results for "".
Improving Dermatologic Care and Access for Gender and Sexual Minority Patients
https://practicaldermatology.com/conferences/aad-2021/improving-dermatologic-care-and-access-for-gender-and-sexual-minority-patients/19919/Dermatologists need increased knowledge of health disparities and tools to best meet the needs of sexual and gender minority patients. From increased risk of skin cancer in sexual minority individuals to acne in the transgender population, there are many dermatologic concerns arising for patients, sAbbVie's Skyrizi Approved, Brooke Shields Endorses SculpSure
https://practicaldermatology.com/topics/psoriasis/dermwire-tv-abbvies-skyrizi-approved-brooke-shi/19607/Skyrizi, an interleukin-23 inhibitor from AbbVie, is FDA approved for the treatment of moderate to severe plaque psoriasis in adults. Brooke Shields is the face of the new “Be strong. Be sexy. Be confident” campaign for SculpSure, from Hologic’s Cynosure. The Noah Worcester Dermatological Society anEczema Discovery; Ortho Dermatologics, Revision, Alastin Product Launches
https://practicaldermatology.com/topics/practice-management/dermwiretv-eczema-discovery-ortho-dermatologics-revision-alastin-product-launches/18353/Regeneron revealed that Dupixent generated sales of $120M within the first nine months of launch. Researchers have identified a possible treatment for moderate-to-severe atopic dermatitis: IL-22 blockade. Product launches or updates from Revision Skincare, Alastin Skincare, Ortho Dermatologics, andTopical Tretinoin: A Versatile Option for Adult Female Acne
https://practicaldermatology.com/issues/supplements/topical-tretinoin-a-versatileoption-for-adult-female-acne/23042/Findings of a roundtable discussion with leading acne experts on the benefits of retinoids for acne patients.Test Your Skills and Learn From Experts on IL-13 Inhibitors in Moderate to Severe Atopic Dermatitis
https://practicaldermatology.com/programs/cme/test-your-skills-and-learn-from-experts-on-il-13-inhibitors-in-moderate-to-severe-atopic-dermatitis/37624/Watch an expert-led case discussion on the role of IL-13 in moderate to severe atopic dermatitis and the efficacy on its inhibition through biologic therapies to achieve control.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-36/23740/Cosmeceuticals: Sunscreens
https://practicaldermatology.com/topics/general-topics/cosmeceuticals-sunscreens/21366/What you should know about the FDA's final ruling on sunscreen products and tips for understanding the variety of sun protection ingredients available to make more informed recommendations to patients.Approvals in Psoriasis and Skin Cancer Highlight a Year of Innovation in Skin Disease Management
https://practicaldermatology.com/topics/skin-cancer-photoprotection/approvals-in-psoriasis-and-skin-cancer-highlight-a-year-of-innovation-in-skin-disease-management/21069/After periods of low drug approval rates, the last year brought several new agents to market.Updates on Nitric Oxide As a Topical Anti-infective
https://practicaldermatology.com/topics/practice-management/updates-on-nitric-oxide-as-a-topical-anti-infective/21071/NO continues to show promise as a safe and effective topical treatment candidate for acne and other infectious dermatoses.Vitamin D and Psoriasis
https://practicaldermatology.com/topics/practice-management/vitamin-d-and-psoriasis/21470/New findings suggest a relationship between psoriasis and vitamin D deficiency, but larger details are still unknown.